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Background: The abundance of circulating endothelial cells (CECs) and circulating endothelial progenitor cells
(CEPs), which serve as surrogate markers for angiogenesis, may be affected by chemotherapy. We studied their
dynamic change during consecutive cycles of chemotherapy.
Methods: We collected blood samples from 15 breast cancer patients, who received a total of 56 courses of
systemic chemotherapy, and measured the CECs, viable CECs (V-CECs), and CEPs by six-color flow cytometry within
the seven days prior to chemotherapy, twice a week during the first and second cycles of chemotherapy, and then
once a week during the subsequent cycles.
Results: The CEC, V-CEC, and CEP levels all significantly decreased from day 1 of treatment to the first week of
chemotherapy. After one week of chemotherapy, the CEC and V-CEC levels returned to a level similar to day 1. The CEP
level remained significantly reduced after the first week of chemotherapy, but gradually rebounded until the next
course of chemotherapy. After six cycles of chemotherapy, the total number of CEC and V-CEC cells trended toward a
decrease and the CEP cells toward an increase. Clinical factors, including the existence of a tumor, chemotherapy
regimens, and the use of granulocyte colony stimulating factor, did not significantly affect these results.
Conclusions: The CEC and CEP counts change dynamically during each course of chemotherapy and after the
chemotherapy cycles, providing background data for any future study planning to use CECs and CEPs as surrogate
markers of angiogenesis in antiangiogenesis treatments combined with chemotherapy.
Keywords: Circulating endothelial cells, Endothelial progenitor cells, Breast cancer, Angiogenesis, BiomarkersBackground
Antiangiogenic drugs play an important role in the
current treatment of cancer. However, single-agent anti-
angiogenesis therapy has had only a modest effect except
in renal cell carcinoma. The combination of antiangio-
genesis drugs and cytotoxic chemotherapy has been
approved for colon, lung, and breast cancers [1-7].
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reproduction in any medium, provided the orsignificantly improves the overall survival of patients
with metastatic colorectal cancer [1,3,4,6-8]. Bevacizumab
can also improve the objective response rate and
progression-free survival of breast and lung cancer
patients treated with chemotherapy [9-18].
Although antiangiogenesis treatments are widely used,
we still lack a surrogate marker to select the populations
for whom the drug will be effective and to define the
optimal biological dose and treatment timing for
antiangiogenic therapy. Currently, the antiangiogenesis
markers that have been extensively studied include
functional imaging, serum angiogenesis-related markers,
and measuring circulating endothelial cells (CECs).
The level of CECs, which are derived from the turn-
over of cells in the blood vessel wall, increases in certain. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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(CEPs), a subpopulation of CECs, have a progenitor-like
phenotype, are derived from bone marrow, and contrib-
ute to the vasculogenesis of late-stage cancer [26-30].
Shaked et al. [31] demonstrated that CECs and CEPs
could serve as surrogate markers to define the optimal
biological dose in antiangiogenesis therapy. The baseline
levels of CEC and CEP and the changes in their levels
from pretreatment to post-treatment may serve as phar-
macodynamic biomarkers to predict responses to antian-
giogenesis therapy and to metronomic chemotherapy
[31-35]. However, animal studies have shown that CEP
mobilization is induced by treatment with the maximal
tolerated dose (MTD) of chemotherapy, such as taxane
and fluorouracil within a few days after the chemotherapy
[36,37]. Preventing CEP mobilization with anti-VEGFR2
blocking antibodies could result in enhanced antitumor
effects [37]. Therefore, the timing of the measurement of
the CECs and CEPS is important when using them as sur-
rogate markers, especially when antiangiogenesis therapy
is combined with MTD chemotherapy. To clarify the dy-
namic pattern of CECs and CEPs, we designed a study to
describe the detailed dynamic change of CECs and CEPs
during each cycle of chemotherapy treatment.
Methods
Patients
Our study was approved by the Research Ethics Commit-
tee of National Taiwan University Hospital. We enrolled
15 breast cancer patients who received systemic chemo-
therapy in the form of neoadjuvant, adjuvant, or palliative
chemotherapy. The patients were required to have
histologically-confirmed breast carcinoma, to be 18 to
70 years old, to have an Eastern Cooperative Oncology
Group (ECOG) performance status of less than 3, and to
have hemoglobin levels above 9.0 mg/dL. Exclusion
criteria were pregnancy, lactation, and uncontrolled
underlying diseases, including active infections, systemic
congestive heart failure, unstable angina, arrhythmia, or
psychiatric disorders. All patients signed informed con-
sents before beginning the study. Blood samples of 10 mL
were drawn within the 7-day period prior to chemother-
apy, then twice a week during first and second cycles of
chemotherapy, and then once a week during the subse-
quent cycles of chemotherapy. The blood samples were
processed for CEC and CEP analysis within 24 hours of
collection (see below). The chemotherapy regimens and
dosages depended on the doctors’ discretion.
Biomarker evaluations
Six-color flow cytometry measured the CECs and CEPs
using a method from Mancuso et al. [19,38]. Red blood
cells were lysed, and then the cell suspensions were evalu-
ated by a BD FACSCanto II cell analyzer (BD Biosciences,San Jose, CA, USA) and FACSDiva software, version 5.0.2
(BD Biosciences), with analysis gates excluding dead cells,
platelets, and debris. We acquired 100,000 events per
sample to analyze the percentage of CECs and CEPs. The
absolute number of CECs and CEPs was then calculated
by multiplying the total white cell count by the percentage
of events collected in the CEC and CEP enumeration
gates. We defined CECs as negative for the hematopoietic
marker CD45 (BD Pharmigen, San Diego, CA) and the
progenitor marker CD133 (Miltenyi Biotec, Bergisch
Glabdach, Germany), and positive for the endothelial mar-
kers CD31 and CD146 (BD Pharmigen). We defined CEPs
as being negative for CD45 and positive for CD31, CD146,
and CD133. We differentiated viable and apoptotic cells
by 7-amino actinomycin D staining [39-41]. Representa-
tive flow cytometry dot plots demonstrating the negative
controls, CEC and CEP gating strategies were provided in
our supplementary data. (Additional file 1: Figure S1,
Additional file 2: Figure S2, Additional file 3: Figure S3,
Additional file 4: Figure S4).
Statistical analysis
Each individual patient received multiple courses of chemo-
therapy and was followed several times during each course
of therapy. The data was two-level (patients and course of
chemotherapy) repeated measurement. The changes in the
levels of CEC, CEP, and viable-CEC (V-CEC) were analyzed
after each course of chemotherapy by a multilevel linear
mixed-effects model with random coefficients. Differences
in the mean levels were considered patient-level random
effects. Each patient’s chemotherapy courses were nested
under the patient level as chemotherapy level. Within each
chemotherapy course, the mean of the measures during the
first week (day 2 to day 7), and the mean of the measures
after the first week (day 8 and beyond) were compared to
the measurement on the day chemotherapy started (day 1,
before chemotherapy started). We analyzed the mean levels
of CEC, CEP, and V-CEC for each chemotherapy course.
We also analyzed how the existence of a tumor during the
course of chemotherapy, the chemotherapy drug, and
the use of granulocyte colony-stimulating factor (GCSF)
affected these measurements. We modeled the correlation
of repeated measurements within the chemotherapy
courses of individual patients by first-order autoregressive
error terms. Two-sided P values less than 0.05 were consid-
ered statistically significant. The “xtmixed” procedure from
the Stata statistical package version 11 (StataCorp LP,
College Station, TX, USA) analyzed the data.
Results
Patient characteristics
Of the 15 patients, 5 were tumor-bearing and 10 were non-
tumor-bearing, with 3 (20%) receiving neoadjuvant chemo-
therapy, 10 (66.7%) receiving adjuvant chemotherapy, and 2
Table 1 Patient characteristics
Characteristic No. of patients %









ER(+), PR(+) 5 33.3%
ER(+), PR(-) 3 20.0%
ER(-), PR(+) 1 6.7%
ER(-), PR(-) 5 33.3%




















not applicable 1 6.7%
Tumor grade
grade 1 2 13.3%
grade 2 6 40.0%
grade 3 6 40.0%






Table 1 Patient characteristics (Continued)
Taxane-based 7 46.7%
Others** 2 13.3%
*pT, pN stage: according to definition of AJCC 7th edition staging system.
**Others include: liposomal doxorubicin, vinorelbine. ER: estrogen receptor; PR:
progesterone receptor; GCSF: Granulocyte colony-stimulating factor.
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Among these fifteen patients, seven (46.7%) had GCSF
administered during their courses of chemotherapy. A
total of seven (46.7%) patients received an anthracycline-
based chemotherapy regimen, seven (46.7%) received a
taxane-based chemotherapy regimen, and two (13.3%)
received other chemotherapy regimens that included
vinorelbine and liposomal doxorubicin. The 15 patients
received a median of four chemotherapy cycles (range: 1–
6 cycles), with a total of 56 courses of chemotherapy over-
all in the study. The average duration between two courses
of chemotherapy was 22.2 days.
Dynamic change of CEC, V-CEC, and CEP number after
chemotherapy
Figure 1 illustrates trends in the levels of CEC, V-CEC,
and CEP as a function of days of chemotherapy post-
operation in one representative patient who was not
tumor-bearing, and as a function of days of chemother-
apy prior to operation in one patient who was tumor-
bearing. The non-tumor-bearing patient (Figure 1A), a
60-year-old woman diagnosed with pT2N2aM0 stage
IIIA breast cancer, received adjuvant TEC chemotherapy
(paclitaxel, epirubicin, cyclophosphamide) for a total of
six cycles after a modified radical mastectomy. The
tumor-bearing patient (Figure 1B), a 56-year-old woman
diagnosed with pT4bN2M0 stage IIIB breast cancer,
received neoadjuvant TEC chemotherapy for a total of
six cycles before a modified radical mastectomy. The
changes in the levels of CEC and CEP of both patients
had a similar wave pattern, with the chemotherapy im-
mediately reducing the CEC and CEP levels followed by
a rebound in their levels. Representative flow cytometry
dot plots data of dynamic change of CEC, CEP and
viable-CEC levels before and after chemotherapy from
one patient was provided in our supplementary data.
(Additional file 5: Figure S5).
During the first week of chemotherapy, the mean CEC
levels decreased by -2.92/μL (95% CI = -4.93, -0.92), V-
CEC by -2.29/μL (95% CI = -3.86, -0.72), and CEP
by -0.37/μL (95% CI = -0.58, -0.15) compared to the day
that chemotherapy started (Figure 2 and Table 2). After
the first week of treatment, their levels of CEC and V-
CEC returned to levels not significantly different from
their levels on the first day of chemotherapy. However,
the level of CEP remained significantly reduced after the
first week of chemotherapy. On the first day of
Figure 1 Standardized trend of CEC, V-CEC, CEP, as a function
of chemotherapy the day before or after tumor resection.
(A) Data from a non-tumor-bearing patient who received adjuvant
chemotherapy after tumor resection. (B) Data from a tumor-bearing
patient who received neoadjuvant chemotherapy before tumor
resection. Chemotherapy immediately reduced the CEC, V-CEC, and
CEP numbers, followed by a rebound elevation of the CEC and CEP
numbers. The “wave” patterns were similar between the non-tumor-
bearing and tumor-bearing patients.
Figure 2 The means and standard deviations of (A) CEC, (B)
V-CEC, and (C) CEP along the course of treatment. Within a
chemotherapy course, the means of the CEC, V-CEC, and CEP were
all significantly decreased in the 1st week of chemotherapy as
compared to the day chemotherapy started. After the 1st week of
treatment, the means of the CEC and V-CEC returned to a level close
to that of the starting day of chemotherapy (Figure 2A, 2B).
However, the mean of the CEP remained significantly reduced after
the 1st week of chemotherapy (Figure 2C). Note that the CEP level
gradually rebounded back to a level similar to or even higher than
the day 1 count of the previous chemotherapy cycle (Figure 2C).
The gray shadow denotes the trends of CEC, V-CEC, and CEP among
the courses of chemotherapy.
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gradually rebounded back to a level similar to or even
higher than the first day of the previous cycle of chemo-
therapy (Figure 2C).
Before chemotherapy was first initiated, the mean
levels CEC and V-CEC were significantly lower as com-
pared to the initiation day of the 1st course of chemo-
therapy (P < 0.01 and P < 0.02, respectively; Table 2).
The level of CEC significantly declined (P = 0.02) and
the V-CEC trended toward a decline over the courses of
chemotherapy (gray shadows in Figure 2). The level of
CEP gradually increased during the first three courses of
chemotherapy and declined during the later treatment
courses (Figure 2C). This “n”-shaped, convex trend was
represented by a set of statistically significant positive
linear (P = 0.02) and negative quadratic (P = 0.02) terms
(Table 2).
Table 2 CEC, V-CEC, CEP trends within and among the chemotherapy courses
Trends within chemotherapy course
Outcome measurement Time point Coefficient (cells/μL) 95% CI p value
CEC start of CT reference
1st wk of CT −2.924 (-4.93,−0.92) < 0.01
after 1st wk of CT −0.909 (-2.80,0.98) 0.35
before 1st CT −5.848 (-9.83,−1.86) < 0.01
V-CEC start of CT reference
1st wk of CT −2.289 (-3.86,−0.72) < 0.01
after 1st wk of CT −0.996 (-2.56,0.57) 0.21
before 1st CT −4.014 (-7.29,−0.73) 0.02
CEP start of CT reference
1st wk of CT −0.366 (-0.58,−0.15) < 0.01
after 1st wk of CT −0.295 (-0.47,−0.12) < 0.01
Trends among courses of chemotherapy
Measurement Terms Coefficient (cells/μL) 95% CI p value
CEC Linear −0.609 (-1.12,-0.10) 0.02
V-CEC Linear −0.288 (-0.72,0.15) 0.19
CEP Linear 0.194 (0.03,0.36) 0.02
Quadratic −0.03 (-0.06,0.01) 0.02
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factors including the presence of a tumor, the operation sta-
tus, the drug used, and the use of GCSF (all P values > 0.1;
Table 3).
Discussion
We have clinically demonstrated the dynamic pattern of
CEC and CEP during the course of chemotherapy treat-
ment. The mean levels of CEC, V-CEC, and CEP all
significantly decreased during the first week of chemo-
therapy. Then the levels of CEC and V-CEC returnedTable 3 CEC, V-CEC, and CEP levels among different clinical c
CEC
Variable Coef* (cells/μL) p value C
Tumor bearing −0.57 0.74
Chemotherapy regimen*
CEF 0.04 0.99





G-CSF use 0.03 0.85
*Coef = adjusted regression coefficient.
*CEF: cyclophosphamide, epirubicin, fluorouracil.
N-HDFL: vinorelbine, continuous infusion fluorouracil and leucovorin.
TCH: docetaxel, carboplatin, herceptin.
TEC: docetaxel, epirubicin, cyclophosphamide.
TH: docetaxel, herceptin.gradually after one week whereas the level of CEP
remained significantly reduced. After six cycles of
chemotherapy, the level of CEC decreased significantly,
V-CEC trended toward a decrease, and CEP increased
significantly. These results were not significantly affected
by clinical factors including the existence of a tumor, the
chemotherapy regimen, and the use of GCSF.
The sole antigen to distinct CEPs with CECs is CD133 at
present. However, human CD133 is not only expressed in
endothelial progenitor cells but also in haematopoietic pro-
genitor cells and bi-potential haemangioblasts. Currently, aonditions
V-CEC CEP
oef (cells/μL) p value Coef (cells/μL) p value
−1.08 0.46 0.10 0.44
0.65 0.82 0.12 0.64
−0.43 0.92 −0.03 0.93
3.22 0.40 0.20 0.55
−0.55 0.82 0.01 0.98
2.50 0.45 0.27 0.32
(Ref) (Ref)
−0.02 0.86 −0.004 0.78
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not feasible and controversial [42]. In our six-color flow
cytometry, CD45 expression can be used to exclude haem-
atopoietic cells from the analysis. Theoretically, CD146 is
expressed in endothelial cells but not platelet, and CD133
expression can be used to differentiate platelet and endo-
thelial microparticles from CEP. However, lack of DNA
staining is at a risk since a nuclear-staining molecule can
be useful to exclude aggregated platelets and/or endothelial
microparticles (which share some surface markers with
CECs and CEPs) from the CEC count [42].
Longitudinal follow-up found that the levels of CEC
and V-CEC increased from the baseline before chemo-
therapy to the first day of the first cycle of chemother-
apy, but this did not occur with the CEPs (Figure 2).
Current thought is that CECs are mature endothelial
cells that have detached from their basement membrane
in response to a blood vessel injury [24,42]. The increase
in CEC and V-CEC levels we observed may be due to
vessel damage caused by implanting port-A catheters or
by tumor resection surgery, since all of the patients were
treated with one of these two procedures before the first
day of the first cycle of chemotherapy. The CEPs are
progenitor cells that are recruited from bone marrow ra-
ther than detached from the vessel wall, and their level
did not change in a similar manner.
Since several studies have indicated that levels of CEC
and CEP correlate with tumor size and grade, [20,40,43-46]
we assumed that tumor-bearing patients would have higher
CEC and CEP levels than patients without tumors, but our
analysis found no significant differences. Perhaps CEC and
CEP levels correlate with not just the presence of a tumor,
but with many factors, including tumor size, tumor grade,
vascular invasion, and lymphatic invasion. Although
patients who received adjuvant chemotherapy mostly had
no gross residual tumor, but vascular or lymphatic inva-
sion, even cancer related cytokines was possible and may
explain for the CEC and CEP kinetics. Since our analysis of
CEC and CEP levels in tumor–bearing and non–tumor
bearing patients included a mix of many variables, we
cannot make a conclusion about which variables affect
their levels. Here we provided some representative figures
of the CEC and CEP kinetics after administration of
chemotherapy in tumor-bearing and non-tumor bearing
patients (Additional file 6: Figure S6). The CEC and CEP
kinetics consistently showed similar wave pattern and had
no obvious differences between patients with and without
tumor bearing. This explanation is also consistent with a
study that found that CEC and CEP levels did not signifi-
cantly change before and after surgery in 15 breast cancer
patients, although vascular invasion and tumor size were
independently associated with the CEC levels [43].
Administering GCSF to mice has been found to ele-
vate CEP and accelerate tumor growth [47-49]. A humanstudy analyzing CEC levels in four patients (one with
seminoma, two with nonseminoma testis cancer, and
one with small-cell lung cancer) receiving chemother-
apy with the support of GCSF found that three out of
four patients had CEC amounts increased 8- to 9-fold
3–8 days after GCSF administration [50]. In the same
study, the CEC level was almost undetectable in
leukopenic patient. This implies that the GCSF effect on
CEC levels may be markedly related to bone marrow re-
covery after chemotherapy. When we compared the
seven patients who received GCSF during chemother-
apy courses to the eight who did not, we found no dif-
ferences in the dynamic trends in the CEC and CEP
levels between these groups. Since our patients received
different chemotherapy regimens and may have differ-
ent grades of bone marrow suppression which lead to
different timing of bone marrow recovery. We suggest
that in our study, the effects of chemotherapy on CEC
and CEP may mask the GCSF effect.
We wanted to understand whether CEC and CEP levels
are affected differently by different chemotherapy agents.
Certain chemotherapy drugs, such as taxane and fluorour-
acil, have been demonstrated to rapidly induce CEP
mobilization and subsequent tumor homing, while others,
such as gemcitabine, cisplatin, and doxorubicin, do not
[37]. Our analysis of 29 cycles of taxane-based chemother-
apy and 26 cycles of non-taxane-based chemotherapy
found no significant differences in the dynamic trends
of these two groups. However, this is not conclusive,
since all of the chemotherapy regimens in this study
used multiple chemotherapy agents and it is difficult to
evaluate the effect of single chemotherapy agent on
CEC/CEP kinetics. We provided some representative
figures of the CEC and CEP kinetics after administration
of different types of chemotherapy regimens in five dif-
ferent patients (Additional file 7: Figure S7). Their CEC
and CEP kinetics consistently show similar wave pat-
tern. It suggests that dynamic changes of CEC and CEP
induced by chemotherapy may have more significant
effect than using different drugs. It supports our conclu-
sion that timing of measurement of CEC and CEP after
chemotherapy should be seriously considered and unified
in the future studies using CEC and CEP as endpoint.
The levels of CEC and V-CEC significantly decreased as
the number of chemotherapy courses progressed (P = 0.02),
but the CEP levels significantly increased during the first
three courses of chemotherapy (P = 0.02) and then declined
during later treatment courses. Although this study
was restricted by the small number of patients and
chemotherapy cycles, the trends we observed were
consistent with the analysis of Furstenberger et al. [39].
They analyzed the levels of CEC and CEP before and after
neoadjuvant chemotherapy in breast cancer patients and
found that, after two cycles of chemotherapy, the CEC
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phenomenon may be explained by the CEPs behaving as
progenitor cells that could be mobilized from the bone
marrow by a regular dose of chemotherapy. Although the
CEPs would gradually differentiate into CECs, the next
course of chemotherapy might destroy some cells that
were in transition before they could fully differentiate into
CECs. This may explain why CEC levels decreased and
CEP levels increased after cycles of chemotherapy.
Many preclinical studies have indicated that CEPs con-
tribute to tumor growth [23,40,43], which warrants fur-
ther concern that chemotherapy may remobilize CEPs
and trigger additional tumor growth. We demonstrated
that the CEC and CEP levels decreased in the first week
of chemotherapy, CEC increased after one week with
each cycle of chemotherapy, and CEP rebounded even
more slowly than CEC. This suggests to us that the rate
of tumor control achieved by chemotherapy may theor-
etically be helped by adding metronomic chemotherapy
or an antiangiogenic agent one week after chemotherapy
to suppress the rebound of CEC and CEP. This hypoth-
esis warrants further prospective study.
Our observation that CEC rebounds earlier than CEP
has two possible explanations: 1) CEP is not the only
source of CEC, which has three main sources: tumor
vasculature, normal vasculature, and CEP. The three
sources could explain why CEC is not fully synchronized
with CEP. 2) The CEPs are a kind of progenitor cell
where one CEP may differentiate into a population of
CECs, which would explain the earlier rise in the slope
of the CECs as compared to the CEPs.
Conclusions
The levels of CEC and CEP change dynamically during
and after each course of chemotherapy. Careful selection
of the timing of sample collection in each chemotherapy
cycle is needed when using CEC and CEP as surrogate
markers of angiogenesis.
Additional files
Additional file 1: Figure S1. CEC and CEP test were preformed within
24 hours of collection of blood samples. The gating strategy is described
below. Exclude debris and red blood cells first. CEC and CEPs are within
CD45dim population (P2). CD31/CD146 double positive population (Q2)
were defined as CECs (S-Figure 1 and 2). Both CD31/CD133 (Q2-1) and
CD146/CD133 (Q2-2) double positive were CEPs (S-Figure 1 and 2). CEPs
number presented here were the average of Q2-1 dot number and Q2-2
dot number. For gating viable-CEC, excluding debris and red blood cells
first and CEC and CEPs are within CD45dim population (P2). CD146 was
CEC maker and 7AAD staining was used to identify the cell viability. Cells
in Q2 are apoptotic CECs and in Q4 are viable CECs. (S-Figure 3 and 4)
Unstain sample was used as a negative control (S-Figure 1 and 3). CEC/
CEP and viable CEP gating was follow the unstain one. (S-Figure 2 and 4).
Additional file 2: Figure S2. CEC and CEP test were preformed within
24 hours of collection of blood samples. The gating strategy is described
below. Exclude debris and red blood cells first. CEC and CEPs are withinCD45dim population (P2). CD31/CD146 double positive population (Q2)
were defined as CECs (S-Figure 1 and 2). Both CD31/CD133 (Q2-1) and
CD146/CD133 (Q2-2) double positive were CEPs (S-Figure 1 and 2). CEPs
number presented here were the average of Q2-1 dot number and Q2-2
dot number. For gating viable-CEC, excluding debris and red blood cells
first and CEC and CEPs are within CD45dim population (P2). CD146 was
CEC maker and 7AAD staining was used to identify the cell viability. Cells
in Q2 are apoptotic CECs and in Q4 are viable CECs. (S-Figure 3 and 4)
Unstain sample was used as a negative control (S-Figure 1 and 3). CEC/
CEP and viable CEP gating was follow the unstain one. (S-Figure 2 and 4).
Additional file 3: Figure S3. CEC and CEP test were preformed within
24 hours of collection of blood samples. The gating strategy is described
below. Exclude debris and red blood cells first. CEC and CEPs are within
CD45dim population (P2). CD31/CD146 double positive population (Q2)
were defined as CECs (S-Figure 1 and 2). Both CD31/CD133 (Q2-1) and
CD146/CD133 (Q2-2) double positive were CEPs (S-Figure 1 and 2). CEPs
number presented here were the average of Q2-1 dot number and Q2-2
dot number. For gating viable-CEC, excluding debris and red blood cells
first and CEC and CEPs are within CD45dim population (P2). CD146 was
CEC maker and 7AAD staining was used to identify the cell viability. Cells
in Q2 are apoptotic CECs and in Q4 are viable CECs. (S-Figure 3 and 4)
Unstain sample was used as a negative control (S-Figure 1 and 3). CEC/
CEP and viable CEP gating was follow the unstain one. (S-Figure 2 and 4).
Additional file 4: Figure S4. CEC and CEP test were preformed within
24 hours of collection of blood samples. The gating strategy is described
below. Exclude debris and red blood cells first. CEC and CEPs are within
CD45dim population (P2). CD31/CD146 double positive population (Q2)
were defined as CECs (S-Figure 1 and 2). Both CD31/CD133 (Q2-1) and
CD146/CD133 (Q2-2) double positive were CEPs (S-Figure 1 and 2). CEPs
number presented here were the average of Q2-1 dot number and Q2-2
dot number. For gating viable-CEC, excluding debris and red blood cells
first and CEC and CEPs are within CD45dim population (P2). CD146 was
CEC maker and 7AAD staining was used to identify the cell viability. Cells
in Q2 are apoptotic CECs and in Q4 are viable CECs. (S-Figure 3 and 4)
Unstain sample was used as a negative control (S-Figure 1 and 3). CEC/
CEP and viable CEP gating was follow the unstain one. (S-Figure 2 and 4).
Additional file 5: Figure S5. Representative flow cytometry dot plot for
defining viable CECs and apoptotic CECs, (A) Exclude debris and red
blood cells. (B) CEC and CEPs are within CD45dim population (P2). (C)
CD146 was CEC maker and 7AAD staining was used to identify the cell
viability. Cells in Q2 are apoptotic CECs and in Q4 are viable
CECsRepresentative data of dynamic change of CEC, CEP (S-Figure 5a, 5c,
5e and 5 g) and viable-CEC (S-Figure 5b, 5d, 5f and 5 h) levels during
second cycle of chemotherapy from one patient. CEC, CEP (S-Figure 5a)
and viable-CEC (S-Figure 5b) at the day before chemotherapy (for this
patient, taxotere /epirubicin /cyclophosphamide) were shown in S-Figure
5a and 5b. Patient’s CEC, CEP and viable-CEC levels were dropping at day
4 and day 7 (S-Figure 5c, 5d, 5e and 5f) after chemotherapy. Three weeks
after chemotherapy, CEC and CEP levels were increased again(S-Figure
5e) and most of the CECs were viable (S-Figure 5f).
Additional file 6: Figure S6. Standardized trend of CEC, V-CEC, CEP, as
a function of chemotherapy the day before tumor resection (A-D), or
after tumor resection.(E-G). The CEC and CEP kinetics consistently showed
similar wave pattern and had no obvious differences between patients
with and without tumor bearing.
Additional file 7: Figure S7. Standardized trend of CEC, V-CEC, CEP, as a
function of different chemotherapy regimens. (A) Data from a patient who
received adjuvant docetaxel, cisplatin, and herceptin. (B) Data from a
patient who received adjuvant cyclophosphamide, epirubicin, and
Fluorouracil. (C) Data from a patient who received adjuvant docetaxel,
epirubicin, and cyclophophamide. (D) Data from a patient who received
neoadjuvant docetaxel, Epirubicin, and cyclophophamide. (E) Data from a
patient who received neoadjuvant vinorelbine and infusion fluorouracil.
Their CEC and CEP kinetics consistently show similar wave pattern. It
suggests that dynamic changes of CEC and CEP induced by chemotherapy
may have more significant effect than using different drugs.
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